{"preliminary_commentary":{"by_channel":{"bluesky_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT06661915","nct_id":"NCT06661915","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06661915. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive ASTX727 PO QD on days 1-5 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo buccal swab sample collection at baseline and blood sample collection and bone marrow aspiration and biopsy throughout the study.","label":"Arm I (ASTX727)","type":"EXPERIMENTAL"},{"description":"Patients receive ASTX727 PO QD on days 1-5 and iadademstat PO QD on days 1-5, 8-12, 15-19, and 22-26 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo buccal swab sample collection at baseline and blood sample collection and bone marrow aspiration and biopsy throughout the study.","label":"Arm II (ASTX727, iadademstat)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-12-31","type":"ESTIMATED"},"conditions":["Accelerated Phase Myeloproliferative Neoplasm","Blast Phase Myeloproliferative Neoplasm","Essential Thrombocythemia","Myelodysplastic/Myeloproliferative Neoplasm","Myeloproliferative Neoplasm, Not Otherwise Specified","Polycythemia Vera","Primary Myelofibrosis","Secondary Myelofibrosis"],"enrollment":{"count":78,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Biospecimen Collection","otherNames":["Biological Sample Collection","Biospecimen Collected","Sample Collection","Specimen Collection"],"type":"PROCEDURE"},{"name":"Bone Marrow Aspiration","otherNames":[],"type":"PROCEDURE"},{"name":"Bone Marrow Biopsy","otherNames":["Biopsy of Bone Marrow","Biopsy, Bone Marrow"],"type":"PROCEDURE"},{"name":"Decitabine and Cedazuridine","otherNames":["ASTX 727","ASTX-727","ASTX727","C-DEC","CDA Inhibitor E7727/Decitabine Combination Agent ASTX727","Cedazuridine/Decitabine Combination Agent ASTX727","Cedazuridine/Decitabine Tablet","DEC-C","Inaqovi","Inqovi"],"type":"DRUG"},{"name":"Iadademstat","otherNames":["ORY 1001","ORY-1001","RG 6016","RG6016","RO 7051790","RO7051790","trans-N1-((1R,2S)-2-Phenylcyclopropyl)-1,4-cyclohexanediamine"],"type":"DRUG"}],"last_update":"2026-09-30","lead_sponsor":"National Cancer Institute (NCI)","official_title":"A Randomized Phase 2 Trial of ASTX727 +/- Iadademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Acute leukemia response-complete (ALR-C) rate","timeFrame":"Within 4 cycles (cycle length = 28 days)"}],"references":[],"start_date":{"date":"2025-08-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)","url":"https://clinicaltrials.gov/study/NCT06661915"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06661915"}